
... a reduced complexity of the bacterial phylum Firmicutes as a signature of the faecal microbiota in patients with CD. It also indicated the presence of new bacterial species.
... a reduced complexity of the bacterial phylum Firmicutes as a signature of the faecal microbiota in patients with CD. It also indicated the presence of new bacterial species.
The data revealed that lactobacilli and the Clostridium leptum subgroup were significantly different between the ulcerated and the nonulcerated regions. It also was noted that for lactobacilli, the composition varied significantly between biopsy sites irrespective of the location of UC in the gut but that the composition of the Clostridium leptum subgroup showed significant differences between paired samples from UC in the rectum and not in the left colon. Localized dysbiosis of the mucosa-associated intestinal microflora, especially for lactobacilli and the Clostridium leptum subgroup, may be closely related to UC.
Washington, Oct 21 (ANI): Lack of a specific bacterium in the gut may be a cause of Crohn’’s disease, an inflammatorygastrointestinal disorder, according to a team of French researchers.
Researchers from the Institut National de la Recherche Agronomique have highlighted the bug, Faecalibacterium prausnitzii, which they show secretes biochemicals that reduce inflammation.
The researchers have already shown that patients with Crohn’’s disease have a marked deficiency in bacteria from the Clostridium leptum group.
Now, their latest study shows that F. prausnitzii, a major component of this group, accounts for a large part of the deficit.
The researchers found that Crohn’’s patients who underwent bowel surgery were more likely to experience a recurrence of the condition if they had low levels of F. prausnitzii.
And in experiments on cultured cells, they showed that liquid in which F. prausnitzii had been grown provided an anti-inflammatory effect.
According to researchers, if the ongoing animal trials prove successful, human patients could benefit from a probiotic treatment with F. prausnitzii.
Dr Anton Emmanuel, medical director of the digestive disorders charity Core, agreed that the study raised the possibility of a therapeutic replacement therapy.
“It would be interesting to see how this finding relates to the emerging body of evidence looking at genetic changes in some patients with Crohn’’s disease, with the known abnormal gene being one that codes for the body’’s ability to recognise foreign bacteria,” BBC quoted Emmanuel, as saying.
The study appears in Proceedings of the National Academy of Sciences. (ANI)
An example of our treatment program is described below.
TESTING:
IgG RAST food panel, Candida antibodies, anti-gliadin antibodies, Vitamin D, B12, folic acid, homocysteine, zinc, iron, ferritin, testosterone (healing in men), and DHEA (healing in both sexes)DIET:
Specific Carbohydrate Diet (tailored to reflect results of IgG RAST)SUPPLEMENTS:
SCD-Compliant Probiotics, Vitamin D, Enteric-coated Fish Oil, EGCG, Curcumin, Zinc, L-glutamine, Methylcobalamin, Methylfolate, DHEAOTHER THERAPIES:
Low-dose Naltrexone, Chrohn's/Colitis intravenous "drips", antifungal medication (Nystatin, Diflucan, etc.), bio-identical testosterone
A reader wrote in and asked:Would you supply me with whatever information you have on dealing with Crohn's disease? I have had it for 36 years and they want to do surgery and remove my large bowel. I don't want to go that route. Any nutritional information you can give me would be helpful. --Pastor David, NEDr Whitaker wrote back:The first thing I would recommend isn't a nutrient but a safe, effective drug that your doctor probably doesn't know about: LOW-DOSE NALTREXONE (LDN). In a recent pilot study, Jill Smith, MD, of the Pennsylvania State College of Medicine treated patients with Crohn's disease with 4.5 MG of LDN at bedtime for 12 weeks, and then followed them for an additonal month. Eighty-nine percent of the participants responded to LDN, and 67 percent went into remission. Dr Smith is now conducting a large phase II placebo-controlled trial of LDN involving children with Crohn's. To learn more vist lowdosenaltrexone.orgDiet modifications are also helpful. But now, you likely know what foods exacerbate your symptoms. If you aren't sure, try eliminating common problematic items such as milk, gluten, citrus, tomatoes, additives, preservatives, sugars, and starches.Crohn's is associated with poor nutritional status, which means a good daily multivitamin is essential. Correcting vitamin D deficiencies alleviates symptoms in some patients, so make sure you get adequate sun exposure and talk to your doctor about testing your blood level of vitamin D (25(OH)D). If its below 50 ng/mL, take enough supplemental vitamin D to bring it into the optimal range.Other supplements with proven benefits for Crohn's disease include aloe vera (I've heard good things about AMP Floracel and Digestinol), the amino acid glutamine, fish oil, curcumin extract (10% of tumeric is curcumin and 90% something else), and probiotics. Look for these supplements in your health food store or call (800) 810-6655 to order.To read more about Crohn's, visit the Subscriber Center at drwhitaker.com. I truly hope these suggestions will improve your condition. Give them a try and let me know how you're doing. -- JW
In the May, 2009 of the Journal of Nutrition, researchers from Beth Israel Deaconess Medical Center and the Massachusetts Institute of Technology report that the amino acid glutamine could help heal the damage caused by H. pylori, the bacteria that causes stomach ulcers and many cases of stomach cancer.
In earlier research, Susan Hagen, PhD and her colleagues discovered that glutamine prevented the death of cultured stomach cells from H. pylori-produced ammonia. For the current experiment, they divided 105 mice to receive standard diets or diets in which L-glutamine replaced 5 percent of total calories. After two weeks, some of the mice in each group were infected with H. pylori. The animals were followed for 20 weeks, during which blood samples were analyzed for antibodies to immune cells that mediate the body’s response to H. Pylori. Additionally, tissue samples were obtained from the stomach and examined for damage, cancer progression and inflammation.
At the end of the 20 week period, infected animals that received L-glutamine had less inflammation than those that received the control diet. "Because many of the stomach pathologies during H. pylori infection are linked to high levels of inflammation, this result provides us with preliminary evidence that glutamine supplementation may be an alternative therapy for reducing the severity of infection," Dr Hagen explained.
"H. pylori bacteria infect more than half of the world's population and were recently identified as a Group 1 carcinogen by the World Health Organization," Dr Hagen added. "Approximately 5.5 percent of the entire global cancer burden is attributed to H. pylori infection and, worldwide, over 900,000 new cases of gastric cancer develop each year. The possibility that an inexpensive, easy-to-use treatment could be used to modify the damaging effects of H. pylori infection warrants further study in clinical trials."